Ikena Oncology Inc. (IKNA): Multiplikator Forward P/S

Logo korporat perusahaan Ikena Oncology (IKNA)

Ikena Oncology, Inc. (IKNA) brings together leading scientists dedicated to the deep pursuit of targeted therapy methods. Despite the search for a buyer and the suspension of its primary project, solid balance sheet liquidity ensures stability. The forward price-to-sales ratio on this chart reflects sentiment dynamics, with the metric settling at 104.50. Business efficiency is increasing through AI automation and robotic design of new drug formulas.

IKNA Ikena Oncology: Kapitalisasi marang prakiraan pendapatan ing interval 04.07.2022 - 07.03.2025

Rincian metrik komprehensif lan analitis Ikena Oncology Inc. (IKNA)

Analisis wiwitan perusahaan:IKNA (Ikena Oncology Inc.)
Produk sing diprodhuksi Ikena Oncology

Ikena Oncology, Inc. (IKNA) focuses on metabolic cancer therapy, where future monopoly patent rights determine the business value. By analyzing the projected P/S multiple, an investor can see the ratio of current market capitalization to expected revenue, which allows for an assessment of the degree of market optimism regarding drug commercialization and helps determine a fair entry threshold for the asset over a long-term horizon.

Analisis pesaing Ikena Oncology, Inc.

Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology Therapeutics (CGON) - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan UroGen Pharma URGN|Rasio rega marang prakiraan pendapatan Bicara Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Genomics PSNL|Multiplikator Forward P/S ERAS|Rasio rega marang pendapatan sing dikarepake DCTH|Y-mAbs Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Aura Biosciences Inc (AURA)|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc.)|SLS: Multiplikator Forward P/S|ACTU: Rasio rega marang pendapatan sing dikarepake|CTOR (Citius Oncology Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tuhurabio.com HURA|Multiplikator Forward P/S TARA|FATE: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S WHWK (Aadi Bioscience)|TCRX (TScan) - Rega mangsa ngarep marang pendapatan|Champions Oncology, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake XBiotech Inc XBIT|CVM: Multiplikator Forward P/S|OSTX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|Multiplikator Forward P/S artivabio.com|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Limited)|Veru - Kapitalisasi marang prakiraan pendapatan|Tempest Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake xiliotx.com (XLO)|Renovaro - Multiplikator Forward P/S|Mural Oncology (MURA) - Multiplikator forward rega marang pendapatan|KAPA: Multiplikator Forward P/S|OKUR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan CytoMed Therapeutics Limited|CRIS: Rega forward marang dodolan|Multiplikator Forward P/S APLM|Multiplikator Forward P/S tharimmune.com (THAR)|Advanced Biomed Corp - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan GNPX|Calidi Biotherapeutics, Inc. - Multiplikator Forward P/S|Sunshine Biopharma (SBFM) - Multiplikator forward rega marang pendapatan|XBIO: Multiplikator Forward P/S|SLRX - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PPBT|Multiplikator Forward P/S American Oncology Network|Rasio rega marang prakiraan pendapatan BeOne Medicines (BGNE)|CKPT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ELEV (Elevation Oncology Inc.)|Multiplikator Forward P/S iCAD Corp ICAD|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S